BHVN at a glance
Biohaven Ltd. (BHVN, SEC CIK 1935979) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on September 10, 2026 and Form 4 insider filings as recently as September 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Biohaven Ltd. (BHVN) shares worth $723.2 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 29 funds
- $723.2M · +0 vs prior quarter
- Latest 8-K
- Sep 10, 2026
- Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Biopharmaceutical development focused on neurological therapies, notably troriluzole
- New financing structure: $250M initial senior secured notes plus up to $350M contingent tranches linked to regulatory approvals
- Strategic shift to revenue-based funding with royalty-like payments of 6.25%+ on global net sales of troriluzole
- Most notable metric: $250 million proceeds received from First Notes in April 2025 under Note Purchase Agreement
- Unique feature: Complex milestone, revenue payment caps, and call/put options tied to FDA/EMA approval timelines and sales benchmarks
Risk Factors
- Key regulatory risk: FDA approval dependency for troriluzole to unlock $150M senior secured notes tranche under April 2025 Note Purchase Agreement
- Geopolitical/macro threat: Tax provision exposure from profitable US and Ireland subsidiaries, with net deferred tax assets fully reserved against realization
- Operational risk: One-time $42.7M cash milestone payment to Knopp in January 2026 related to 2025 Additional Consideration under Knopp Amendment
- Competitive risk: Royalty buyback of $867.5M milestone payments to Knopp reduces future payments but exposes to mid-single digit flat royalty on Kv7 programs
- Financial risk: Liquidity pressure with net operating loss and $609.4M cash used in operations in 2025 despite $230M cash and $89.2M marketable securities on hand
Management Discussion & Analysis
- No management outlook, guidance, or key emerging risks mentioned
- Text focuses on industry data sources, estimates, and trademark notices
AI summary of the BHVN 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Product revenue $0, with no product sales revenue generated
- Commercial pipeline led by BHV-1300, BHV-1400, opakalim and taldefgrobep
- Near-term milestones: RISE 3 results, taldefgrobep Phase 2 results and BHV-1400 pivotal study targeted for second half of 2026
Risk Factors
- No risk-factors section provided in the submitted filing excerpt
- No newly added or materially updated risks identifiable from the excerpt
- No regulatory, legal, operational, competitive, market, or financial risks disclosed in the excerpt
AI summary of the BHVN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- FDA partial clinical hold pauses new BHV-7000 enrollment after insufficient metabolite safety information from rodent testing
- Dosing continues for more than 600 randomized patients, including fully enrolled BHV7000-303
Item 7.01: Regulation FD Disclosure
- Biohaven announced a transaction under its License Agreement, including assumption of certain obligations to Knopp
- Exhibit 99.1 contains the press release and transaction details investors should review
Item 1.01: Entry into a Material Definitive Agreement
- Exclusive worldwide Kv7 license to SKBP, centered on Phase 2/3 epilepsy drug opakalim, subject to antitrust clearance and closing conditions
- $400M upfront: $350M at closing and $50M one year later, plus up to $150M development and regulatory milestones
Item 2.02: Results of Operations and Financial Condition
- Item 2.02 section contains only an incorporation-by-reference disclaimer
- No earnings figures, reporting period, or operating metrics provided in the supplied text
Item EX-99.1: Item EX-99.1
- Q2 2026 net loss narrowed to $137.3M, or $0.91/share, from $198.1M, reflecting lower development spending
- Cash, securities and restricted cash totaled approximately $270.5M, while notes payable reached $259.5M
AI summaries of BHVN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BHVN
Don't miss the next BHVN filing
- Alerts as it files. A push when BHVN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BHVN, by share count.
- Ask anything. An AI agent that reads every BHVN filing and answers with sources.
BHVN alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Gentile Kimberly | A | Sep 15, 2026 | 1,000 | - |
| HUGIN ROBERT J | A | Apr 28, 2026 | 68,693 | - |
| Heffernan Michael Thomas | A | Apr 28, 2026 | 68,693 | - |
| Bailey Gregory | A | Apr 28, 2026 | 68,693 | - |
| Mehta Kishan | A | Apr 28, 2026 | 68,693 | - |
| CHILDS JOHN W | A | Apr 28, 2026 | 68,693 | - |
| GREGORY JULIA P | A | Apr 28, 2026 | 68,693 | - |
| Antonijevic Irina | A | Apr 28, 2026 | 68,693 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$436.1M | -$885.1M | -$745.4M |
| Net Income | -$408.2M | -$846.4M | -$738.8M |
| Balance Sheet | |||
| Total Assets | $513.2M | $615.1M | $451.4M |
| Equity | - | $423.4M | $52.1M |
| ROE | - | -199.9% | -1418.8% |
| Per Share | |||
| EPS | $-5.73 | $-9.28 | $-6.86 |
| Cash Flow | |||
| Operating CF | -$331.7M | -$582.5M | -$609.4M |
| CapEx | $3.0M | $4.0M | $715K |
Source: XBRL data in Biohaven Ltd. (BHVN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate BHVN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 29 | $723.2M |
| Q1 2026 | 29 | $362.7M |
| Q4 2025 | 24 | $466.3M |
| Q3 2025 | 26 | $487.6M |
| Q2 2025 | 26 | $505.2M |
| Q1 2025 | 26 | $552.9M |
| Q4 2024 | 22 | $701.1M |
| Q3 2024 | 17 | $394.0M |
- AQR Capital Management+2.18M (+110%)
- BlackRock+1.99M (+18%)
- D.E. Shaw & Co+1.34M (+47%)
- Bank of America Corp+718.4K (+95%)
- FMR LLC (Fidelity)+605.6K (+26%)
- Millennium Management−1.03M (-71%)
- T. Rowe Price Group−760.3K (-34%)
- Two Sigma Investments−742.9K (-63%)
- Morgan Stanley−185.6K (-18%)
- Citadel Advisors LLC−103.4K (-6%)
- Allstate+15.4K
- Principal Financial Group+10.2K
- Marex Group plc−50.3K
- Franklin Resources−20.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 199 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BHVN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 17, 2026 | - | - | - |
| 8-K | Sep 10, 2026 | - | Analysis | - |
| 8-K | Aug 26, 2026 | - | Analysis | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 7, 2026 | - | Analysis | - |
| 8-K | Jul 9, 2026 | - | Analysis | - |
| 8-K | May 27, 2026 | - | Analysis | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 8-K | May 4, 2026 | - | Analysis | - |
| 10-Q | May 4, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 4, 2026 | - | Analysis | - |
| 4 | Apr 30, 2026 | - | - | - |
| 4 | Apr 30, 2026 | - | - | - |
| 4 | Apr 30, 2026 | - | - | - |
| 4 | Apr 30, 2026 | - | - | - |
| 4 | Apr 30, 2026 | - | - | - |
| 4 | Apr 30, 2026 | - | - | - |
| 4 | Apr 30, 2026 | - | - | - |
| 4 | Mar 19, 2026 | - | - | - |
| 4 | Mar 9, 2026 | - | - | - |
| 4 | Mar 3, 2026 | - | - | - |
| 10-K | Mar 2, 2026 | Dec 31, 2025 | Analysis | |
| 8-K | Mar 2, 2026 | - | Analysis | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
BHVN SEC filings: frequently asked questions
Which institutions hold BHVN stock?
As of June 30, 2026, the largest Biohaven Ltd. (BHVN) holders among the 13F filers tracked by SignalX were BlackRock ($196.6 million), State Street Corp ($103.4 million), D.E. Shaw & Co ($62.4 million), AQR Capital Management ($61.8 million), FMR LLC (Fidelity) ($44.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the main risks in BHVN's latest 10-K?
In the 10-K filed March 2, 2026, Biohaven Ltd. (BHVN) flagged: Key regulatory risk: FDA approval dependency for troriluzole to unlock $150M senior secured notes tranche under April 2025 Note Purchase Agreement. Geopolitical/macro threat: Tax provision exposure from profitable US and Ireland subsidiaries, with net deferred tax assets fully reserved against realization. (AI summary of the Risk Factors section.)
What did BHVN report in its latest 8-K?
Biohaven Ltd. (BHVN) filed an 8-K on September 10, 2026 reporting Item 8.01 (Other Events). FDA partial clinical hold pauses new BHV-7000 enrollment after insufficient metabolite safety information from rodent testing.
What are the latest BHVN SEC filings?
Biohaven Ltd. (BHVN) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on September 10, 2026 and a Form 4 insider filing on September 17, 2026.
What is BHVN's SEC CIK number?
Biohaven Ltd. (BHVN)'s SEC Central Index Key (CIK) is 1935979. EDGAR lists every BHVN filing under that number.
Ask anything about BHVN
The research agent reads BHVN's filings, financials, insider trades and 13F holders, then answers with sources.